50% off Premium Yearly
The momentum has broken badly and has a high PE. But he entered this on a rebound that has momentum. Despite an upgrade today, he doesn't see a green light ahead.
Stock price when the opinion was issued
As of Jun 12, 2026. Market Open.
Projected 19% earnings growth in 2026, yet trades at under 12x PE 2026. Has a robust drug pipeline.
Build your watch list
Sign in to track investmentsyou care about
CNBC
RN Croft Financial Group
5i Research
Stockchase Premium
Private Wealth Management, ScotiaMcleod
The momentum has broken badly and has a high PE. But he entered this on a rebound that has momentum. Despite an upgrade today, he doesn't see a green light ahead.